Chemotherapy versus best supportive care for extensive small cell lung cancer

Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases

“…Small cell carcinoma of the lung (SCLC) accounts for 18%-20% of all lung cancers and is invariably associated with a dismal prognosis [51,52] . Median overall survival is 9-10 mo despite treatment in extensive SCLC and 18-24 mo in case of LD SCLC [53,54] . Role of surgical resection in SCLC is limited with treatment being primarily combined chemoradiation [54] .…”

Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases

“…Small cell carcinoma of the lung (SCLC) accounts for 18%-20% of all lung cancers and is invariably associated with a dismal prognosis [51,52] . Median overall survival is 9-10 mo despite treatment in extensive SCLC and 18-24 mo in case of LD SCLC [53,54] . Role of surgical resection in SCLC is limited with treatment being primarily combined chemoradiation [54] .…”

Chemotherapy use and outcomes in patients with stage III or IV small-cell lung cancer in relation to age: An analysis of the English Systemic Anti-Cancer Treatment (SACT) dataset

“…While chemotherapy is the accepted mainstay of treatment for SCLC, there is no direct randomized evidence of its superiority over supportive care 5 . There has been little progress with new cytotoxic chemotherapy agents or combinations over many years though recent trials have shown modest survival benefits with the addition of immunotherapy to platinum based chemotherapy in extensive disease 6 , 7 .…”

Knockdown of neuron‑specific enolase suppresses the proliferation and migration of NCI‑H209 cells

“…Of patients with SCLC, it is reported that 60–70% have developed metastasis at the point of diagnosis (3). Untreated patients with SCLC rapidly succumb to the disease within 2–4 months (4). Patients with limited-stage SCLC are usually treated with chemo- and radiotherapy and with consecutive prophylactic cranial irradiation in the case of intracranial metastasis (5,6), while chemotherapy is the primary choice for patients with extensive-stage disease (7).…”

Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases

“…Small cell carcinoma of the lung (SCLC) accounts for 18%-20% of all lung cancers and is invariably associated with a dismal prognosis [51,52] . Median overall survival is 9-10 mo despite treatment in extensive SCLC and 18-24 mo in case of LD SCLC [53,54] . Role of surgical resection in SCLC is limited with treatment being primarily combined chemoradiation [54] .…”

Chemotherapy use and outcomes in patients with stage III or IV small-cell lung cancer in relation to age: An analysis of the English Systemic Anti-Cancer Treatment (SACT) dataset

“…While chemotherapy is the accepted mainstay of treatment for SCLC, there is no direct randomized evidence of its superiority over supportive care 5 . There has been little progress with new cytotoxic chemotherapy agents or combinations over many years though recent trials have shown modest survival benefits with the addition of immunotherapy to platinum based chemotherapy in extensive disease 6 , 7 .…”

Knockdown of neuron‑specific enolase suppresses the proliferation and migration of NCI‑H209 cells

“…Of patients with SCLC, it is reported that 60–70% have developed metastasis at the point of diagnosis (3). Untreated patients with SCLC rapidly succumb to the disease within 2–4 months (4). Patients with limited-stage SCLC are usually treated with chemo- and radiotherapy and with consecutive prophylactic cranial irradiation in the case of intracranial metastasis (5,6), while chemotherapy is the primary choice for patients with extensive-stage disease (7).…”

Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases

“…Small cell carcinoma of the lung (SCLC) accounts for 18%-20% of all lung cancers and is invariably associated with a dismal prognosis [51,52] . Median overall survival is 9-10 mo despite treatment in extensive SCLC and 18-24 mo in case of LD SCLC [53,54] . Role of surgical resection in SCLC is limited with treatment being primarily combined chemoradiation [54] .…”

Chemotherapy use and outcomes in patients with stage III or IV small-cell lung cancer in relation to age: An analysis of the English Systemic Anti-Cancer Treatment (SACT) dataset

“…While chemotherapy is the accepted mainstay of treatment for SCLC, there is no direct randomized evidence of its superiority over supportive care 5 . There has been little progress with new cytotoxic chemotherapy agents or combinations over many years though recent trials have shown modest survival benefits with the addition of immunotherapy to platinum based chemotherapy in extensive disease 6 , 7 .…”

Knockdown of neuron‑specific enolase suppresses the proliferation and migration of NCI‑H209 cells

“…Of patients with SCLC, it is reported that 60–70% have developed metastasis at the point of diagnosis (3). Untreated patients with SCLC rapidly succumb to the disease within 2–4 months (4). Patients with limited-stage SCLC are usually treated with chemo- and radiotherapy and with consecutive prophylactic cranial irradiation in the case of intracranial metastasis (5,6), while chemotherapy is the primary choice for patients with extensive-stage disease (7).…”